WellSky Expands Partnership with Adoration for Enhanced Home Health Services
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 19 2026
0mins
Source: Yahoo Finance
- Partnership Expansion: WellSky has expanded its collaboration with Adoration Home Health by extending clinical coding and documentation advisory services, aiming to enhance the quality of post-acute care technology and services, which is expected to significantly improve patient care experiences.
- Star Rating Improvement: Since partnering with WellSky in 2023, the percentage of Adoration locations achieving a CMS Home Health Star Rating of 4 or higher has surged from 21.7% and is projected to reach 90% by 2026, which will enhance reimbursement and performance security for the organization.
- AI Technology Integration: WellSky is innovating its coding, billing, and accounts receivable workflows through the integration of SkySense AI™, helping post-acute care clients improve service quality and operational efficiency, thereby strengthening their competitive position in the market.
- Industry Trust: WellSky is trusted by the majority of the nation’s largest home health providers to support critical coding and revenue cycle workflows, reflecting its commitment to driving high-quality performance in complex value-based care environments.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BTSG?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BTSG
Wall Street analysts forecast BTSG stock price to fall
12 Analyst Rating
12 Buy
0 Hold
0 Sell
Strong Buy
Current: 60.830
Low
40.00
Averages
43.20
High
50.00
Current: 60.830
Low
40.00
Averages
43.20
High
50.00
About BTSG
BrightSpring Health Services, Inc. provides complementary home- and community-based pharmacy and provider health solutions for complex populations in need of specialized and/or chronic care. Through the Company’s service lines, including pharmacy, home health care and rehabilitation, it provides comprehensive and more integrated care and clinical solutions in all 50 states to customers, clients and patients. Its services are organized and managed through two reportable segments: Pharmacy Solutions and Provider Services. Pharmacy Solutions segment operates long-term institutional pharmacies, hospice pharmacies, specialty oncology pharmacies, and home infusion centers. It provides infused, injectable, and oral medication services in the home and clinic. Provider Services segment provides a variety of services to help manage the whole-person health of its patients in their homes and communities through services such as home health care and hospice care and long-term specialty care.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Four Stocks with Rising Cash Flows to Enhance Your Portfolio
- BrightSpring Health Services: BrightSpring continues to benefit from strong demand for home-based care, with the 2026 earnings estimate revised upward by 9.3% to $1.64, indicating significant growth potential in health solutions.
- StoneX Group: StoneX's financial services business saw its fiscal 2026 earnings estimate increase by 3.4% to $6.00 per share over the past 30 days, reflecting robust performance and market confidence in the financial sector.
- Orion Group: Orion's 2026 earnings estimate rose from 36 cents to 37 cents per share, with an expected 48% year-over-year growth, showcasing strong demand and expansion capabilities in the infrastructure construction market.
- Flexsteel Industries: Flexsteel's earnings estimate was revised upward by 2.8% to $4.78 per share in the past week, demonstrating ongoing growth and adaptability in the furniture manufacturing sector.
See More
BrightSpring Health Services 2026 Strategic Adjustments
- Revenue Pressure Analysis: BrightSpring anticipates approximately $600 million in revenue headwinds for 2026, primarily due to reimbursement changes related to the Inflation Reduction Act and brand-to-generic conversions, which will have a long-term impact on the company's overall financial performance.
- Pharmacy and Service Integration: The company operates integrated pharmacy and healthcare services across all 50 states, serving over 475,000 patients daily, demonstrating its competitive advantage in coordinated care and value-based models, particularly among seniors and specialty populations.
- Specialty Drug Growth: In Q1 2026, Specialty and Infusion revenue rose 36% year-over-year to $2.64 billion, driven by an increase in limited distribution drugs and enhanced commercial execution, showcasing BrightSpring's strong growth potential in the market.
- Profitability Enhancement: Despite facing policy and conversion pressures, BrightSpring raised its 2026 adjusted EBITDA guidance to $795 million to $825 million, indicating the company's confidence in future revenue and efficiency improvements.
See More
BrightSpring Health Services Raises 2026 Outlook Following Strong Q1 Performance
- Revenue Outlook Raised: BrightSpring has increased its 2026 revenue forecast to $14.725 billion to $15.225 billion, up from the previous range of $14.450 billion to $15.00 billion, indicating strong confidence in future growth, particularly in pharmacy and provider services.
- Profitability Improvement: The adjusted EBITDA range has been lifted to $795 million to $825 million, reflecting management's confidence in margin expansion, which is expected to offset revenue pressures from policy changes through efficiency gains and business integration.
- Strong Q1 Performance: BrightSpring reported adjusted earnings per share of 39 cents in the first quarter, exceeding the market expectation of 29 cents and more than doubling year-over-year, showcasing significant improvements in profitability and market competitiveness.
- Healthy Cash Flow Position: By the end of the first quarter, BrightSpring had $888.8 million in cash and cash equivalents, a substantial increase from $88.4 million in the prior quarter, indicating improved financial flexibility that supports future debt reduction and selective reinvestment.
See More
BrightSpring Health Services Exceeds Financial Expectations
- Financial Performance Surge: BrightSpring reported a net income of $74 million and net revenue of $3.61 billion for Q1 2026, significantly up from $9 million and $2.88 billion in the same quarter last year, showcasing strong performance in complex population health services.
- Adjusted EBITDA Growth: The adjusted EBITDA for Q1 2026 reached $190 million, a 44.8% increase from $131 million in Q1 2025, indicating successful operational efficiency and cost control measures.
- Upgraded Full-Year Revenue Guidance: BrightSpring raised its revenue outlook for 2026 to between $14.725 billion and $15.225 billion, up from the previous range of $14.450 billion to $15.00 billion, reflecting optimism about market demand.
- Stock Price Milestone: The stock price hit an all-time high of $59.65 yesterday, reflecting strong investor confidence in the company's future growth potential and further solidifying its market position on Nasdaq.
See More
BRIGHTSPRING HEALTH SERVICES INC: TD COWEN INCREASES TARGET PRICE FROM $60 TO $65
Price Increase Announcement: BrightSpring Health Services has raised its target price to $65 from $60.
Company Overview: BrightSpring Health Services is a provider of health services, focusing on various healthcare solutions.
See More
BrightSpring Health Services Q1 2026 Earnings Highlights
- Strong Financial Performance: BrightSpring reported total revenue of $3.6 billion in Q1 2026, reflecting a 26% year-over-year growth, indicating the company's sustained growth potential in the healthcare sector, with full-year revenue expected to range from $14.725 billion to $15.225 billion, showcasing optimism for future market conditions.
- Adjusted EBITDA Growth: The adjusted EBITDA for the first quarter reached $190 million, a 45% increase year-over-year, with an EBITDA margin improving to 5.3%, demonstrating significant progress in cost control and operational efficiency, thereby enhancing the company's financial stability.
- Community Business Sale Proceeds: BrightSpring completed the sale of Community Living on March 30, 2026, generating approximately $811 million in net cash proceeds, which will be utilized for debt repayment and enhancing cash flow, further optimizing the company's capital structure.
- Pharmacy Solutions Outlook: Despite a 9% decline in Home and Community Pharmacy revenue to $527 million, primarily due to IRA impacts, the company continues to maintain healthy growth in its specialty and infusion businesses, expecting to offset this decline through the expansion of LDD product lines and improved patient satisfaction scores.
See More
Four Stocks with Rising Cash Flows to Enhance Your Portfolio
- BrightSpring Health Services: BrightSpring continues to benefit from strong demand for home-based care, with the 2026 earnings estimate revised upward by 9.3% to $1.64, indicating significant growth potential in health solutions.
- StoneX Group: StoneX's financial services business saw its fiscal 2026 earnings estimate increase by 3.4% to $6.00 per share over the past 30 days, reflecting robust performance and market confidence in the financial sector.
- Orion Group: Orion's 2026 earnings estimate rose from 36 cents to 37 cents per share, with an expected 48% year-over-year growth, showcasing strong demand and expansion capabilities in the infrastructure construction market.
- Flexsteel Industries: Flexsteel's earnings estimate was revised upward by 2.8% to $4.78 per share in the past week, demonstrating ongoing growth and adaptability in the furniture manufacturing sector.
See More
BrightSpring Health Services 2026 Strategic Adjustments
- Revenue Pressure Analysis: BrightSpring anticipates approximately $600 million in revenue headwinds for 2026, primarily due to reimbursement changes related to the Inflation Reduction Act and brand-to-generic conversions, which will have a long-term impact on the company's overall financial performance.
- Pharmacy and Service Integration: The company operates integrated pharmacy and healthcare services across all 50 states, serving over 475,000 patients daily, demonstrating its competitive advantage in coordinated care and value-based models, particularly among seniors and specialty populations.
- Specialty Drug Growth: In Q1 2026, Specialty and Infusion revenue rose 36% year-over-year to $2.64 billion, driven by an increase in limited distribution drugs and enhanced commercial execution, showcasing BrightSpring's strong growth potential in the market.
- Profitability Enhancement: Despite facing policy and conversion pressures, BrightSpring raised its 2026 adjusted EBITDA guidance to $795 million to $825 million, indicating the company's confidence in future revenue and efficiency improvements.
See More
BrightSpring Health Services Raises 2026 Outlook Following Strong Q1 Performance
- Revenue Outlook Raised: BrightSpring has increased its 2026 revenue forecast to $14.725 billion to $15.225 billion, up from the previous range of $14.450 billion to $15.00 billion, indicating strong confidence in future growth, particularly in pharmacy and provider services.
- Profitability Improvement: The adjusted EBITDA range has been lifted to $795 million to $825 million, reflecting management's confidence in margin expansion, which is expected to offset revenue pressures from policy changes through efficiency gains and business integration.
- Strong Q1 Performance: BrightSpring reported adjusted earnings per share of 39 cents in the first quarter, exceeding the market expectation of 29 cents and more than doubling year-over-year, showcasing significant improvements in profitability and market competitiveness.
- Healthy Cash Flow Position: By the end of the first quarter, BrightSpring had $888.8 million in cash and cash equivalents, a substantial increase from $88.4 million in the prior quarter, indicating improved financial flexibility that supports future debt reduction and selective reinvestment.
See More
BrightSpring Health Services Exceeds Financial Expectations
- Financial Performance Surge: BrightSpring reported a net income of $74 million and net revenue of $3.61 billion for Q1 2026, significantly up from $9 million and $2.88 billion in the same quarter last year, showcasing strong performance in complex population health services.
- Adjusted EBITDA Growth: The adjusted EBITDA for Q1 2026 reached $190 million, a 44.8% increase from $131 million in Q1 2025, indicating successful operational efficiency and cost control measures.
- Upgraded Full-Year Revenue Guidance: BrightSpring raised its revenue outlook for 2026 to between $14.725 billion and $15.225 billion, up from the previous range of $14.450 billion to $15.00 billion, reflecting optimism about market demand.
- Stock Price Milestone: The stock price hit an all-time high of $59.65 yesterday, reflecting strong investor confidence in the company's future growth potential and further solidifying its market position on Nasdaq.
See More
BRIGHTSPRING HEALTH SERVICES INC: TD COWEN INCREASES TARGET PRICE FROM $60 TO $65
Price Increase Announcement: BrightSpring Health Services has raised its target price to $65 from $60.
Company Overview: BrightSpring Health Services is a provider of health services, focusing on various healthcare solutions.
See More
BrightSpring Health Services Q1 2026 Earnings Highlights
- Strong Financial Performance: BrightSpring reported total revenue of $3.6 billion in Q1 2026, reflecting a 26% year-over-year growth, indicating the company's sustained growth potential in the healthcare sector, with full-year revenue expected to range from $14.725 billion to $15.225 billion, showcasing optimism for future market conditions.
- Adjusted EBITDA Growth: The adjusted EBITDA for the first quarter reached $190 million, a 45% increase year-over-year, with an EBITDA margin improving to 5.3%, demonstrating significant progress in cost control and operational efficiency, thereby enhancing the company's financial stability.
- Community Business Sale Proceeds: BrightSpring completed the sale of Community Living on March 30, 2026, generating approximately $811 million in net cash proceeds, which will be utilized for debt repayment and enhancing cash flow, further optimizing the company's capital structure.
- Pharmacy Solutions Outlook: Despite a 9% decline in Home and Community Pharmacy revenue to $527 million, primarily due to IRA impacts, the company continues to maintain healthy growth in its specialty and infusion businesses, expecting to offset this decline through the expansion of LDD product lines and improved patient satisfaction scores.
See More
